RxDoctor Payments Data

Ingrid Ramirez Diaz

Gynecologic Oncology · Ponce, PRNPI 1194987552

Payments from drug & device makers

What this record shows

This record is dominated by education: $20,000 of the $29,272 with a category attached, or 68.3%. Intuitive Surgical accounts for 80.8% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $12,033, more than ten times the $100 reported in 2019.

$29,272in general payments, 2019–2025

Across 129 payments — averaging $226.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$24K
  • Merck$3K
  • AstraZeneca$930
  • AbbVie$222
  • GSK$185
  • Hologic Sales And Service, LLC$163
  • plus $726 from 12 others

What the payments were for

  • Consulting fees$1,9006%
  • Speaking & faculty fees$1,1254%
  • Travel & lodging$2,5359%
  • Food & beverage$3,71213%
  • Education$20,00068%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical31$23,659
Merck20$3,387
AstraZeneca36$930
AbbVie6$222
GSK8$185
Hologic Sales And Service, LLC6$163
Eisai Inc.2$149
Pfizer7$141
BD1$102
Johnson And Johnson International1$100
Seagen Inc.3$58
Stryker1$48
Tempus AI, Inc2$30
Caris MPI, Inc.1$25
Clovis Oncology, Inc.1$22
Fennec Pharmaceuticals, Inc.1$18
Immunogen, Inc.1$17
PBG Puerto Rico LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib22$187,141
Ondansetron Hcl46$953
Estradiol17$848
Famotidine60$524
Clobetasol Propionate11$524
Lidocaine-PrilocaineLidocaine/Prilocaine32$474
Metoclopramide Hcl45$342
Gabapentin14$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$930$187,14122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other gynecologic oncology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →